Cencora, Inc. $COR Shares Acquired by B. Metzler seel. Sohn & Co. AG

B. Metzler seel. Sohn & Co. AG grew its stake in Cencora, Inc. (NYSE:COR) by 141.5% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 17,847 shares of the company’s stock after buying an additional 10,458 shares during the quarter. B. Metzler seel. Sohn & Co. AG’s holdings in Cencora were worth $4,963,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of COR. Bank of America Corp DE lifted its holdings in shares of Cencora by 62.3% in the 4th quarter. Bank of America Corp DE now owns 5,193,807 shares of the company’s stock valued at $1,166,944,000 after buying an additional 1,994,256 shares during the period. Castlekeep Investment Advisors LLC acquired a new position in Cencora in the 4th quarter worth about $399,508,000. GAMMA Investing LLC raised its holdings in Cencora by 43,561.9% in the 1st quarter. GAMMA Investing LLC now owns 1,598,461 shares of the company’s stock worth $444,516,000 after purchasing an additional 1,594,800 shares during the period. Invesco Ltd. raised its holdings in Cencora by 42.1% in the 1st quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock worth $1,281,429,000 after purchasing an additional 1,364,433 shares during the period. Finally, T. Rowe Price Investment Management Inc. raised its holdings in Cencora by 4,459.6% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 997,233 shares of the company’s stock worth $277,321,000 after purchasing an additional 975,362 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Jefferies Financial Group upped their price target on Cencora from $275.00 to $300.00 and gave the stock a “hold” rating in a report on Monday, June 30th. Robert W. Baird upped their price target on Cencora from $314.00 to $350.00 and gave the stock an “outperform” rating in a report on Thursday, May 8th. Morgan Stanley set a $330.00 price target on Cencora and gave the stock an “equal weight” rating in a report on Wednesday, July 16th. Citigroup upped their price target on Cencora from $330.00 to $355.00 and gave the stock a “buy” rating in a report on Thursday, May 8th. Finally, Wells Fargo & Company upped their price target on Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a report on Wednesday, August 13th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and a consensus target price of $311.25.

Insider Buying and Selling

In other news, CEO Robert P. Mauch sold 4,968 shares of the company’s stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $294.11, for a total value of $1,461,138.48. Following the completion of the sale, the chief executive officer directly owned 42,351 shares in the company, valued at $12,455,852.61. This represents a 10.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Chairman Steven H. Collis sold 14,578 shares of the stock in a transaction that occurred on Tuesday, July 22nd. The stock was sold at an average price of $292.67, for a total value of $4,266,543.26. Following the completion of the transaction, the chairman owned 309,913 shares of the company’s stock, valued at $90,702,237.71. The trade was a 4.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 34,125 shares of company stock valued at $9,993,789 over the last 90 days. Company insiders own 10.80% of the company’s stock.

Cencora Price Performance

NYSE:COR opened at $290.69 on Thursday. Cencora, Inc. has a 12 month low of $218.65 and a 12 month high of $309.35. The stock has a 50 day moving average of $293.21 and a two-hundred day moving average of $281.27. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64. The firm has a market cap of $56.36 billion, a P/E ratio of 29.91, a price-to-earnings-growth ratio of 1.37 and a beta of 0.58.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.21. The business had revenue of $80.66 billion during the quarter, compared to analyst estimates of $80.34 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The business’s revenue was up 8.7% compared to the same quarter last year. During the same period in the prior year, the business earned $3.34 earnings per share. On average, analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th will be given a $0.55 dividend. The ex-dividend date is Friday, August 15th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.8%. Cencora’s dividend payout ratio is 22.63%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.